Skip to content

Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020

Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04514874
Acronym
Covaé
Enrollment
479
Registered
2020-08-17
Start date
2020-09-01
Completion date
2020-12-31
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, SARS-CoV Infection

Brief summary

The aeronautical community was also affected and greatly impacted economically and socially by the Covid-19 pandemic. Away from the acute phase, the epidemiological impact and the consequences of this disease within the French aviation flight crew population must be assessed. This study is aimed at providing original epidemiological data among civil and military aircrew, prior to possible prevention strategies or countermeasures to optimize risk management in terms of aviation safety and to promote, if necessary, future targeted studies.

Interventions

OTHERQuestionnaire

Self-questionnaire about socio-demographical status, health status and lifestyle habits during and following the COVID-19 pandemic.

Sponsors

Direction Centrale du Service de Santé des Armées
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At least 18 years of age * Professional military aircrew * Presenting himself/herself for a periodic medical exam

Exclusion criteria

* Under 18 years of age * Parachutists * Non-professional aircrew * Presenting himself/herself for a first medical exam * Pregnant woman, parturient, breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of COVID-19 infection among French military professional aircrewAt enrollmentPrevalence of COVID-19 infection will be estimated on the basis of the replies to the questionnaire

Secondary

MeasureTime frameDescription
Techniques used for COVID-19 screeningAt enrollmentTechniques used for COVID-19 screening will be estimated on the basis of the replies to the questionnaire (among participants who reported being tested for COVID-19)
Reasons for COVID-19 screeningAt enrollmentReasons for COVID-19 screening will be estimated on the basis of the replies to the questionnaire (among participants who reported being tested for COVID-19)
Experienced symptoms of COVID-19At enrollmentExperienced symptoms of COVID-19 will be estimated on the basis of the replies to the questionnaire (among participants who reported being infected)
Predictive factors of COVID-19 infectionAt enrollmentPredictive factors of COVID-19 infection will be assessed using a top-down logistic regression model taking into account socio-demographic and occupational variables.
Social consequences of the COVID-19 pandemicAt enrollmentSocial consequences of the COVID-19 pandemic will be estimated on the basis of the replies to the questionnaire
Factors associated with pejorative consequences of the COVID-19 pandemicAt enrollmentFactors associated with pejorative consequences of the COVID-19 pandemic will be assessed using a top-down logistic regression model taking into account socio-demographic and occupational variables.
Medical care of COVID-19At enrollmentMedical care of COVID-19 will be estimated on the basis of the replies to the questionnaire (among participants who reported being infected)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026